GlassScriptPhysician profile
Haleh Moazen
NPI 1427147750
$32,285.63
in general payments reported to CMS, 2019-2025
44 companies · $6,319 in 2025
The $6,319 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,743 · 2020: $2,720 · 2021: $3,297 · 2022: $5,265 · 2023: $4,931 · 2024: $6,010 · 2025: $6,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,259.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,463.38 | 2019-2025 | Wegovy, Ozempic |
| Abbvie INC. | $3,966.24 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $3,304.07 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,852.30 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $2,659.84 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Teva Pharmaceuticals USA, INC. | $1,797.97 | 2019-2024 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,189.88 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Amgen INC. | $1,117.91 | 2019-2024 | Repatha, Otezla, Prolia |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $802.99 | 2019-2024 | |
| Lilly USA, LLC | $746.24 | 2024-2025 | Kisunla, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $714.79 | 2019-2022 | |
| Gilead Sciences, INC. | $700.79 | 2019-2025 | Vemlidy, Veklury |
| Abbott Laboratories | $690.87 | 2024-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $502.06 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $501.45 | 2020-2025 | Cobenfy, Camzyos |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haleh Moazen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.